Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096128 | 0.86 | SLC18A3 (0.46) | SLC18A3SLC6A2SLC6A4GRIN2BLTA4H | |
| SCHEMBL27010674 | 0.83 | SLC18A3 (0.60) | SLC18A3SLC6A2SLC6A4GRIN2BLTA4H | |
| SCHEMBL26879524 | 0.80 | SLC18A3 (0.50) | SLC18A3SLC6A2SLC6A4GRIN2BLTA4H | |
| SCHEMBL20063747 | 0.77 | SLC18A3 (0.68) | SLC18A3GRIN2BLTA4HEBPL3MBTL1 | |
| SCHEMBL8079394 | 0.75 | KDM1A (0.44) | SLC18A3GRIN2B | |
| SCHEMBL17007249 | 0.75 | SLC18A3 (0.45) | SLC18A3SLC6A2SLC6A4GRIN2BMEN1 | |
| SCHEMBL20073123 | 0.74 | OPRM1 (0.35) | SLC18A3 | |
| SCHEMBL3375958 | 0.74 | GRIN2B (0.60) | SLC18A3SLC6A2SLC6A4GRIN2BDPP4 | |
| SCHEMBL9455273 | 0.72 | GRIN2B (0.58) | SLC18A3SLC6A2SLC6A4GRIN2BDPP4 | |
| Hydrochloric Acid SCHEMBL9454768 | 0.71 | GRIN2B (0.57) | SLC18A3SLC6A2SLC6A4GRIN2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SLC18A3 2528/4885SLC6A2 633/4885SLC6A4 1294/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SLC18A3 2402/4885SLC6A2 608/4885SLC6A4 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.